The Government of Canada funds NMIN through the Networks of Centres of Excellence (NCE) Program.

NMIN awarded the $200,000 CAD grant to Asep in conjunction with the firm's collaborative partners on the project at the Hancock Lab at the University of British Columbia (UBC), as well as NMIN PharmaCore, a subsidiary of NMIN that provides pharmacology, toxicology, and scale-up manufacturing expertise at UBC.

The funds will be used for pre-clinical studies to establish the technology's pharmacokinetic and pharmacodynamic properties, as well as its toxicology parameters, to guide dosing regimens.

The information will contribute to a pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) and advance the technology toward clinical trials, Asep Medical said.

Modified bacterial peptide shows early promise against drug-resistant pathogens
Work to improve the potency and reduce the toxicity of an antimicrobial peptide has yielded a molecule that inhibited multidrug-resistant bacteria (MDR)...

Scientists offer way to overcome barriers to nucleic acid delivery
Scientists from Australia's Monash University have suggested ways of overcoming the challenges in delivering nucleic acid therapeutics, including engineering...

Clarametyx touts biofilm study
Clarametyx Biosciences touted the results of a study published November 3 in Cell that provides insight about components in bacterial biofilms...

Novel microscopy method unlocks clues to nanomedicine interactions
A new mixed microscopy method has led to a better understanding of the interactions of proteins in the body with nanoparticles used for biotherapeutic...